medigraphic.com
ISSN 2594-3006 (Digital)
ISSN 2007-1752 (Impreso)
Archivos de Medicina de Urgencia de México

2024, Número 1

<< Anterior Siguiente >>

Arch Med Urg Mex 2024; 16 (1)


Neurorehabilitación farmacológica en el infarto cerebral: el potencial de cerebrolysin

Cantú-Brito C, Arellano-Ramírez A, Hernández-Cruz MJ, Galván-Merlos MA

Idioma: Español
Referencias bibliográficas: 35
Paginas: 12-21
Archivo PDF: 790.52 Kb.


RESUMEN

La rehabilitación neurológica ha logrado notables avances para restablecer las funciones motoras relacionadas con EVC. Alrededor del 40% de los pacientes que desarrollan afección motora del miembro superior permanecen discapacitados a pesar de recibir fisioterapia intensiva. Por ello, se ha enfatizado en la necesidad de contar con intervenciones farmacológicas que influyan en la neurorrehabilitación de personas con disfunción motora. La presente revisión analiza el potencial de Cerebrolysin en la recuperación motora funcional en pacientes con EVC sustentado en evidencia experimental de ciencias básicas y estudios de neuroimagen que evalúan la neuroplasticidad, así como su Inclusión en las Guías de Rehabilitación Motora en Pacientes con Infarto Cerebral Agudo.
Finalmente, la combinación de rehabilitación física con fármacos neuro reparadores es un enfoque terapéutico novedoso. Cerebrolysin proporciona efectos favorables en la restauración de la función motora, preserva la integridad de la red motora durante el proceso de reorganización neuronal después del infarto cerebral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of CardiovascularDiseases and Risk Factors, 1990-2019: Update Fromthe GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.doi:10.1016/j.jacc.2020.11.010.

  2. Feigin VL, Stark BA, Johnson CO, et al. Global, regional, andnational burden of stroke and its risk factors, 1990–2019: a systematicanalysis for the Global Burden of Disease Study 2019.Lancet Neurol. 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0.

  3. Ouriques Martins SC, Sacks C, Hacke W, et al. Priorities to reducethe burden of stroke in Latin American countries. Lancet Neurol.2019;18(7). doi:10.1016/S1474-4422(19)30068-7.

  4. Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization(WSO): Global Stroke Fact Sheet 2022. International Journal ofStroke. 2022;17(1). doi:10.1177/17474930211065917.

  5. Cruz-Góngora VD la, Chiquete E, Gómez–Dantés H, Cahuana-Hurtado L, Cantú-Brito C. Trends in the burden of stroke inMexico: A national and subnational analysis of the global burdenof disease 1990–2019. The Lancet Regional Health - Americas.2022;10. doi:10.1016/j.lana.2022.100204.

  6. Gorelick PB. The global burden of stroke: persistent and disabling.Lancet Neurol. 2019;18(5). doi:10.1016/S1474-4422(19)30030-4

  7. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T,Tahamtan U, Rezaei Y. Cerebrolysin effects on neurological outcomesand cerebral blood flow in acute ischemic stroke. NeuropsychiatrDis Treat. 2014;10. doi:10.2147/NDT.S75304.

  8. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetidefor the treatment of acute ischaemic stroke (ESCAPE-NA1): amulticentre, double-blind, randomised controlled trial. The Lancet.2020;395(10227). doi:10.1016/S0140-6736(20)30258-0.

  9. Russo C, Veronelli L, Casati C, et al. Explicit motor sequencelearning after stroke: a neuropsychological study. Exp Brain Res.2021;239(7). doi:10.1007/s00221-021-06141-5.

  10. Whitehead S, Baalbergen E. Post-stroke rehabilitation. SouthAfrican Medical Journal. 2019;109(2). doi:10.7196/SAMJ.2019.v109i2.00011.

  11. van der Vliet R, Selles RW, Andrinopoulou ER, et al. PredictingUpper Limb Motor Impairment Recovery after Stroke: A MixtureModel. Ann Neurol. 2020;87(3). doi:10.1002/ana.25679.

  12. Gladstone DJ, Danells CJ, Black SE. The Fugl-Meyer Assessmentof Motor Recovery after Stroke: A Critical Review of Its MeasurementProperties. Neurorehabil Neural Repair. 2002;16(3).doi:10.1177/154596802401105171.

  13. Bliźniewska-Kowalska K, Łukasik M, Gałecki P. Cerebrolysin –mechanism of action and application in psychiatry and neurology.Pharmacotherapy in Psychiatry and Neurology. 2019;35(1).doi:10.33450/fpn.2019.03.002.

  14. Fiani B, Covarrubias C, Wong A, et al. Cerebrolysin for stroke,neurodegeneration, and traumatic brain injury: review of the literatureand outcomes. Neurological Sciences. 2021;42(4):1345-1353. doi:10.1007/s10072-021-05089-2.

  15. Zhang L, Chopp M, Meier DH, et al. Sonic hedgehog signaling pathwaymediates Cerebrolysin-improved neurological function afterstroke. Stroke. 2013;44(7). doi:10.1161/STROKEAHA.111.000831

  16. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD. A double-blind, placebo-controlled, randomized trial to evaluate the safetyand efficacy of cerebrolysin in patients with Acute ischaemicStroke in Asia - CASTA. International Journal of Stroke. 2009;4(5).doi:10.1111/j.1747-4949.2009.00340.x.

  17. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for theearly management of patients with acute ischemic stroke: 2019update to the 2018 guidelines for the early management of acuteischemic stroke a guideline for healthcare professionals from theAmerican Heart Association/American Stroke Association. Stroke.2019;50(12). doi:10.1161/STR.0000000000000211.

  18. Chamorro Á, Dirnagl U, Urra X, Planas AM. Neuroprotection inacute stroke: Targeting excitotoxicity, oxidative and nitrosativestress, and inflammation. Lancet Neurol. 2016;15(8). doi:10.1016/S1474-4422(16)00114-9.

  19. Ladurner G, Kalvach P, Moessler H. Neuroprotective treatment withCerebrolysin in patients with acute stroke: A randomised controlledtrial. J Neural Transm. 2005;112(3). doi:10.1007/s00702-004-0248-2.

  20. Moessler H. Efficacy and Safety of Cerebrolysin Treatment in EarlyRecovery after Acute Ischemic Stroke: A Randomized, Placebo-Controlled, Double-Blinded, Multicenter Clinical Trial. Vol 10.

  21. Ziganshina LE, Abakumova T, Hoyle CHV. Cerebrolysin for acuteischaemic stroke. Cochrane Database of Systematic Reviews.2020;2020(7). doi:10.1002/14651858.CD007026.pub6.

  22. Muresanu DF, Strilciuc S, Stan A. Current Drug Treatment of AcuteIschemic Stroke: Challenges and Opportunities. CNS Drugs.2019;33(9). doi:10.1007/s40263-019-00663-x.

  23. Gharagozli K, Harandi AA, Houshmand S, et al. Efficacy and safetyof Cerebrolysin treatment in early recovery after acute ischemicstroke: a randomized, placebo-controlled, double-blinded, multicenterclinical trial. J Med Life. 2017;10(3).

  24. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesisin the ischemic brain and improves functional outcome afterstroke. J Neurosci Res. 2010;88(15). doi:10.1002/jnr.22495

  25. Brainin M. Cerebrolysin: a multi-target drug for recovery afterstroke. Expert Rev Neurother. 2018;18(8). doi:10.1080/14737175.2018.1500459.

  26. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin andRecovery After Stroke (CARS): A randomized, placebo-controlled,double-blind, multicenter trial. Stroke. 2016;47(1). doi:10.1161/STROKEAHA.115.009416.

  27. Lyle RC. A performance test for assessment of upper limb functionin physical rehabilitation treatment and research. International Journalof Rehabilitation Research. 1981;4(4). doi:10.1097/00004356-198112000-00001.

  28. Goodglass, H., & Kaplan E. The Assessment of Aphasia and RelatedDisorders (2nd edition). In: Boston Diagnostic Aphasia ExaminationBooklet. ; 1983.

  29. Guekht A, Heiss D, Gusev E, Vester J, Doppler E, Muresanu D.Cerebrolysin and recovery after stroke (CARS 2): a randomized,placebo-controlled, double-blind, multicenter clinical study. J NeurolSci. 2015;357. doi:10.1016/j.jns.2015.08.336.

  30. Guekht A, Vester J, Heiss WD, et al. Safety and efficacy of Cerebrolysinin motor function recovery after stroke: a meta-analysis ofthe CARS trials. Neurological Sciences. 2017;38(10). doi:10.1007/s10072-017-3037-z.

  31. DeBoer SR, Hubbard R, Mersha M, Pinilla Monsalve G, Winter S,Zeiler SR. Enhanced Spontaneous Motor Recovery After Strokein Mice Treated With Cerebrolysin. Neurorehabil Neural Repair.2021;35(6). doi:10.1177/15459683211000734.

  32. Chang WH, Park C hyun, Kim DY, et al. Cerebrolysin combinedwith rehabilitation promotes motor recovery in patients with severemotor impairment after stroke. BMC Neurol. 2016;16(1).doi:10.1186/s12883-016-0553-z.

  33. Chang WH, Lee J, Shin Y Il, et al. Cerebrolysin combined withrehabilitation enhances motor recovery and prevents neural networkdegeneration in ischemic stroke patients with severe motordeficits. J Pers Med. 2021;11(6). doi:10.3390/jpm11060545.

  34. Stinear CM, Lang CE, Zeiler S, Byblow WD. Advances andchallenges in stroke rehabilitation. Lancet Neurol. 2020;19(4).doi:10.1016/S1474-4422(19)30415-6.

  35. Erratum: Guidelines for adult stroke rehabilitation and recovery:A guideline for healthcare professionals from the AmericanHeart Association/American Stroke Association (Stroke (2016)47 (e98-e169) DOI: 10.1161/STR.0000000000000098). Stroke.2017;48(12). doi:10.1161/STR.0000000000000156.




2020     |     www.medigraphic.com